We need you! Join our contributor community and become a WikEM editor through our open and transparent promotion process.
User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 23:09, 29 September 2016 (diff | hist) . . (+4) . . Toxicology (main) (→Toxicological Exam)
- 23:08, 29 September 2016 (diff | hist) . . (+12) . . Toxicology (main) (→Management)
- 23:08, 29 September 2016 (diff | hist) . . (+14) . . Toxicology (main) (→See Also)
- 23:07, 29 September 2016 (diff | hist) . . (+17) . . Toxicology (main) (→Management)
- 23:06, 29 September 2016 (diff | hist) . . (+59) . . Toxicology (main) (→Toxicological Exam)
- 23:05, 29 September 2016 (diff | hist) . . (+217) . . Toxicology (main) (→Management)
- 23:01, 29 September 2016 (diff | hist) . . (+324) . . Toxicology (main) (→Background)
- 20:28, 28 September 2016 (diff | hist) . . (+27) . . N Urinalysis (Redirected page to Urine analysis) (current)
- 20:27, 28 September 2016 (diff | hist) . . (+27) . . N UA (Redirected page to Urine analysis) (current)
- 20:26, 28 September 2016 (diff | hist) . . (-25) . . Needed pages (→Suggestions (Add/Delete as made))
- 20:25, 28 September 2016 (diff | hist) . . (+98) . . Urine analysis
- 20:21, 28 September 2016 (diff | hist) . . (+5,000) . . N Urine analysis (Created page with "==Reference Range== {| {{table}} | Color||Yellow |- | Clarity/turbidity||Clear |- | pH||4.5-8.0 |- | Specific gravity||1.005-1.025 |- | Glucose||<130 mg/d |- | Ketones||None |...")
- 19:16, 28 September 2016 (diff | hist) . . (+25) . . Rifampin (→General)
- 19:14, 28 September 2016 (diff | hist) . . (+8) . . Abnormally colored urine (→Orange)
- 19:13, 28 September 2016 (diff | hist) . . (+30) . . Phenazopyridine (→See Also)
- 19:12, 28 September 2016 (diff | hist) . . (+28) . . N Azo (Redirected page to Phenazopyridine) (current)
- 19:12, 28 September 2016 (diff | hist) . . (+28) . . N Pyridium (Redirected page to Phenazopyridine) (current)
- 19:10, 28 September 2016 (diff | hist) . . (+1,456) . . N Phenazopyridine (Created page with "==Administration== *Type: Genitourinary *Dosage Forms: 100, 200 mg *Routes of Administration: PO *Common Trade Names: Pyridium, Azo Urinary Pain Relief, Uricalm Max, Uristat...")
- 19:00, 28 September 2016 (diff | hist) . . (0) . . Sulfhemoglobinemia (→Background)
- 18:59, 28 September 2016 (diff | hist) . . (0) . . Sulfhemoglobinemia (→Background)
- 18:59, 28 September 2016 (diff | hist) . . (+1,083) . . N Sulfhemoglobinemia (Created page with "==Background== *Occurs when a sulfer atom binds to porphyrin ring of hemoglobin, resulting in permanent oxidation of iron to the ferric state, incapable of oxygen transport *M...")
- 18:51, 28 September 2016 (diff | hist) . . (+23) . . Methemoglobinemia (→See Also)
- 18:24, 28 September 2016 (diff | hist) . . (+60) . . Polycystic kidney disease (→Evaluation)
- 18:22, 28 September 2016 (diff | hist) . . (+236) . . Polycystic kidney disease (→Clinical Features)
- 18:17, 28 September 2016 (diff | hist) . . (+41) . . Polycystic kidney disease (→Background)
- 18:17, 28 September 2016 (diff | hist) . . (+164) . . Polycystic kidney disease (→Clinical Features)
- 18:15, 28 September 2016 (diff | hist) . . (+87) . . Polycystic kidney disease (→Background)
- 18:11, 28 September 2016 (diff | hist) . . (+69) . . Hepatitis A (→Clinical Features)
- 18:10, 28 September 2016 (diff | hist) . . (+21) . . Hepatitis A (→See Also)
- 18:09, 28 September 2016 (diff | hist) . . (+271) . . Hepatitis A (→Management)
- 18:02, 28 September 2016 (diff | hist) . . (+397) . . Hepatitis A (→Clinical Features)
- 17:42, 28 September 2016 (diff | hist) . . (+30) . . Nerve and regional blocks (main) (→Specific Nerve Blocks)
- 17:38, 28 September 2016 (diff | hist) . . (+18) . . Fenoldopam (→See Also)
- 17:37, 28 September 2016 (diff | hist) . . (+62) . . Fenoldopam (→Mechanism of Action)
- 17:36, 28 September 2016 (diff | hist) . . (+50) . . Fenoldopam (→Pharmacology)
- 17:35, 28 September 2016 (diff | hist) . . (+218) . . Fenoldopam (→Common)
- 17:34, 28 September 2016 (diff | hist) . . (+78) . . Fenoldopam (→Serious)
- 17:33, 28 September 2016 (diff | hist) . . (+173) . . Fenoldopam (→Contraindications)
- 17:24, 28 September 2016 (diff | hist) . . (+17) . . Ribavarin (→See Also)
- 17:23, 28 September 2016 (diff | hist) . . (+65) . . Ribavarin (→Administration)
- 17:17, 28 September 2016 (diff | hist) . . (+332) . . Kanamycin (→Contraindications)
- 00:26, 27 September 2016 (diff | hist) . . (-1) . . Facial cellulitis (→Background)
- 23:19, 26 September 2016 (diff | hist) . . (0) . . Facial cellulitis (→Evaluation)
- 23:18, 26 September 2016 (diff | hist) . . (-30) . . Needed pages (→Suggestions (Add/Delete as made))
- 23:17, 26 September 2016 (diff | hist) . . (+1,811) . . N Facial cellulitis (Created page with "==Background== *Superficial soft tissue infection of the face *Risk factors include immunosuppression, diabetes, vascular injury (due to radiation or trauma), foreign bodies *...")
- 23:16, 26 September 2016 (diff | hist) . . (+23) . . Cellulitis (→See Also) (current)
- 22:40, 26 September 2016 (diff | hist) . . (-17) . . Needed pages (→Suggestions (Add/Delete as made))
- 22:39, 26 September 2016 (diff | hist) . . (+1,391) . . Thalassemia
- 22:22, 26 September 2016 (diff | hist) . . (+1,800) . . N Thalassemia (Created page with "==Background== *A group of hereditary disorders resulting in microcytic, hypochromic, hemolytic anemia *Most common in Mediterranean, Middle Eastern, African and Southeast Asi...")
- 21:46, 26 September 2016 (diff | hist) . . (+10) . . Exfoliative erythroderma (→See Also)
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
